Verrica Pharmaceuticals Inc. (VRCA) Reports $5.7M YCANTH Revenue, Up 57.9% Year Over Year

Verrica reported Q3 2026 U.S. YCANTH net product revenue of $5.7M, up 11.9% from the prior quarter and 57.9% year over year, and total revenue of $6.9M. It unlocked access to $27.5M in growth capital and expects cash to fund operations through both common-warts trial readouts.Material DetailsContex…